Next Article in Journal
Molecular Analysis of ZNF71 KRAB in Non-Small-Cell Lung Cancer
Next Article in Special Issue
Correction of Heritable Epigenetic Defects Using Editing Tools
Previous Article in Journal
Modeling Rett Syndrome with Human Pluripotent Stem Cells: Mechanistic Outcomes and Future Clinical Perspectives
Previous Article in Special Issue
Clinical and Molecular Diagnosis of Beckwith-Wiedemann Syndrome with Single- or Multi-Locus Imprinting Disturbance

Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention

Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio, 80138 Naples, Italy
U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania “Luigi Vanvitelli”, 80138 Naple, Italy
Author to whom correspondence should be addressed.
Academic Editor: Emanuela Viggiano
Int. J. Mol. Sci. 2021, 22(7), 3753;
Received: 11 March 2021 / Revised: 27 March 2021 / Accepted: 2 April 2021 / Published: 4 April 2021
(This article belongs to the Special Issue Molecular Research in Medical Genetics)
Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most common cause of cancer-related deaths in men. Family history of PCa, hereditary breast and ovarian cancer (HBOC) and Lynch syndromes (LS), are among the most important risk factors compared to age, race, ethnicity and environmental factors for PCa development. Hereditary prostate cancer (HPCa) has the highest heritability of any major cancer in men. The proportion of PCa attributable to hereditary factors has been estimated in the range of 5–15%. To date, the genes more consistently associated to HPCa susceptibility include mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) and homologous recombination genes (BRCA1/2, ATM, PALB2, CHEK2). Additional genes are also recommended to be integrated into specific research, including HOXB13, BRP1 and NSB1. Importantly, BRCA1/BRCA2 and ATM mutated patients potentially benefit from Poly (ADP-ribose) polymerase PARP inhibitors, through a mechanism of synthetic lethality, causing selective tumor cell cytotoxicity in cell lines. Moreover, the detection of germline alterations in MMR genes has therapeutic implications, as it may help to predict immunotherapy benefits. Here, we discuss the current knowledge of the genetic basis for inherited predisposition to PCa, the potential target therapy, and the role of active surveillance as a management strategy for patients with low-risk PCa. Finally, the current PCa guideline recommendations are reviewed. View Full-Text
Keywords: hereditary prostate cancer; genetic testing; genotype–phenotype correlation; surveillance hereditary prostate cancer; genetic testing; genotype–phenotype correlation; surveillance
Show Figures

Figure 1

MDPI and ACS Style

Vietri, M.T.; D’Elia, G.; Caliendo, G.; Resse, M.; Casamassimi, A.; Passariello, L.; Albanese, L.; Cioffi, M.; Molinari, A.M. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. Int. J. Mol. Sci. 2021, 22, 3753.

AMA Style

Vietri MT, D’Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. International Journal of Molecular Sciences. 2021; 22(7):3753.

Chicago/Turabian Style

Vietri, Maria T., Giovanna D’Elia, Gemma Caliendo, Marianna Resse, Amelia Casamassimi, Luana Passariello, Luisa Albanese, Michele Cioffi, and Anna M. Molinari 2021. "Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention" International Journal of Molecular Sciences 22, no. 7: 3753.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop